Distinct Impex Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Distinct Impex Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $69.7K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Distinct Impex Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $69.7K Trade | TransData Nexus

Distinct Impex Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $69.7K Total Trade · DGFT Verified

Distinct Impex Private Limited is an Indian pharmaceutical exporter with a total trade value of $69.7K across 2 products in 1 therapeutic categories. Based on 16 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Mitomycin ($50.7K), Tofacitinib ($19.0K), .

Distinct Impex Private Limited — Export Portfolio & Destination Treemap

Distinct Impex Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Distinct Impex Private Limited? — Company Overview & Market Position

Distinct Impex Private Limited is an Indian pharmaceutical exporter established on April 29, 2019, in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U51909MH2019PTC324647. It operates as a private limited company with an authorized capital of ₹500,000 and a paid-up capital of ₹375,140. The registered office is located at Unit No.1 (Part B), Hitex Industrial Estate, Vardhman Compound, S V Road, Dahisar East, Mumbai, Maharashtra, 400068. Distinct Impex specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily focusing on the Advanced Oncology therapeutic category.

What Does Distinct Impex Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Mitomycin$50.7K 2Tofacitinib$19.0K

Distinct Impex Private Limited Therapeutic Categories — 1 Specializations

Product Portfolio — Top 2 by Export Value

Distinct Impex Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Mitomycin	Advanced Oncology	$50.7K	9	0.6%	9
2	Tofacitinib	Advanced Oncology	$19.0K	7	0.5%	10

Distinct Impex Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $69.7K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Distinct Impex Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Distinct Impex Private Limited's manufacturing facilities are situated in Mumbai, Maharashtra. The company emphasizes quality assurance in its production processes, ensuring that all pharmaceutical formulations meet industry standards. Specific details regarding manufacturing capacities and specializations are not publicly disclosed.

3Key Leadership

As of September 30, 2025, the directors of Distinct Impex Private Limited are Manthan Shah Rohit and Manan Harish Shah. The company's leadership is committed to maintaining high standards in pharmaceutical manufacturing and export operations. Detailed information about other key executives, such as the CEO, CFO, and other senior management personnel, is not publicly available.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Distinct Impex Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Distinct Impex Private Limited's export activities are primarily focused on the Advanced Oncology therapeutic category, with significant exports of Mitomycin and Tofacitinib. The company has engaged in 16 shipments totaling $70,000 USD, with Mitomycin accounting for $51,000 USD and Tofacitinib for $19,000 USD. These products are exported to various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. Specific regulatory filings, approvals, and market access statuses in these regions are not publicly disclosed.

2Emerging Markets

Distinct Impex Private Limited has expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's focus on the Advanced Oncology therapeutic category aligns with the increasing demand for cancer treatments in these regions. While the company has pursued WHO prequalification to enhance access to these markets, specific details regarding the status of such prequalification are not publicly available.

3Geographic Strategy

Distinct Impex Private Limited's export portfolio is concentrated in the Advanced Oncology therapeutic category, with Mitomycin and Tofacitinib being the primary products. This concentration indicates a strategic focus on oncology treatments. The company's geographic diversification into emerging markets suggests a strategy to mitigate risks associated with overreliance on a single market or product. However, the lack of diversification in product offerings may expose the company to market fluctuations within the oncology segment.

Distinct Impex Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Distinct Impex Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export activities to the United States suggest compliance with FDA regulations; however, detailed records are not accessible.

2WHO & EU GMP

Distinct Impex Private Limited emphasizes quality assurance in its manufacturing processes. While the company has pursued WHO prequalification to enhance access to international markets, specific details regarding the status of such prequalification are not publicly available. Similarly, information about EU Good Manufacturing Practice (GMP) certifications or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not disclosed.

3CDSCO & Indian Regulatory

Distinct Impex Private Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) are not publicly available.

Distinct Impex Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Distinct Impex Private Limited operates in the competitive pharmaceutical export market, focusing on the Advanced Oncology therapeutic category. Key competitors include other Indian pharmaceutical exporters specializing in oncology treatments. While specific market share comparisons are not publicly available, the company's concentration on Mitomycin and Tofacitinib positions it within a niche segment of the oncology market.

2Key Differentiators

Distinct Impex Private Limited's focus on the Advanced Oncology therapeutic category, particularly in exporting Mitomycin and Tofacitinib, differentiates it in the pharmaceutical export market. The company's commitment to quality assurance and compliance with international standards further enhances its competitive position.

3Strategic Position

Distinct Impex Private Limited's strategic direction centers on exporting finished pharmaceutical formulations in the oncology segment. The company's expansion into emerging markets indicates a proactive approach to growth and market diversification. Future outlooks may involve broadening the product portfolio and enhancing regulatory approvals to strengthen its position in the global pharmaceutical export market.

Buyer Due Diligence Brief — Evaluating Distinct Impex Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Distinct Impex Private Limited demonstrates a consistent track record in exporting pharmaceutical formulations, with 16 shipments totaling $70,000 USD. The company's focus on quality assurance and compliance with regulatory standards indicates reliability in its export operations. However, the concentration on a limited number of products may impact the consistency of export volumes.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

WHO-GMP Certification: Verify the status of WHO prequalification for the company's products.

EU GMP Certification: Check for compliance with European Union Good Manufacturing Practices.

Frequently Asked Questions — Distinct Impex Private Limited

How many pharmaceutical products does Distinct Impex Private Limited export from India?

Distinct Impex Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Mitomycin ($50.7K), Tofacitinib ($19.0K). Total export value is $69.7K.

What is Distinct Impex Private Limited's total pharmaceutical export value?

Distinct Impex Private Limited's total pharmaceutical export value is $69.7K, based on 16 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Distinct Impex Private Limited cover?

Distinct Impex Private Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full Distinct Impex Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.